Report from the Melanoma Independent Board First Melanoma MIB Conference, 21-22 October 2013

Testori, A.; Ascierto, P.; Chiarion Sileni, V.; De Lorenzo, F.; Pelicci, P. G.; Rossi, C. R.
June 2014
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
Academic Journal
The Melanoma Independent Board (MIB) held its first conference from 21 to 22 October, 2013, in Rome, Italy. Like the MIB itself, the conference brought together specialists from all aspects of cancer care: doctors, patient associations, journalists, and representatives from local government, hospitals, and pharma to encourage an interdisciplinary discussion on the future of melanoma. It was hoped that the conference would be an opportunity for all participants to see and understand each other's points of view. In memoriam of melanoma pioneer Natalie Cascinelli, the conference focussed on innovation and sustainability as well as the latest drug developments.


Related Articles

  • European Institute of Oncology inaugurated in Milan. Vanchieri, Cori // JNCI: Journal of the National Cancer Institute;6/1/94, Vol. 86 Issue 11, p827 

    Reports on the inauguration of the European Institute of Oncology in Milan, Italy. Staff; Agreements with European academic institutes regarding career issues.

  • Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum].  // Breast Cancer: Targets & Therapy;Mar2018, Vol. 11, p51 

    No abstract available.

  • AVBCC 2013 Steering Committee.  // American Health & Drug Benefits;Jul2013, Vol. 6 Issue 5, p236 

    A list of the members of the Association for Value-Based Cancer Care 2013 Steering Committee is presented including Burt Zweigenhaft, Craig K. Deligdish and Gary M. Owens.

  • Enthusiasm High for Anti-PD-1 Agents.  // Personalized Medicine in Oncology;Aug2014, Vol. 3 Issue 5, p296 

    No abstract available.

  • Conference report. Harmer, Victoria // Cancer Nursing Practice;May2012, Vol. 11 Issue 4, p10 

    The article offers information on the 8th European Breast Cancer Conference held in Vienna in March 2012.

  • Collaboration in Cancer Trials.  // Oncologist;2015 Supplement, Vol. 20, pS1 

    Abstracts of papers discussed during the 2015 Chabner Colloquium held on October 26-27, 2015 at The Liberty Hotel, Boston, Massachusetts are presented including "CAR Therapy--The CD19 Paradigm" by Michel Sadelain, "Cancer Vaccines and Immunomodulatory Therapy" by David E. Avigan and "Genomic...

  • Delcath enters launch and training agreements with IEO.  // Medical Device Daily;11/28/2011, Vol. 15 Issue 226, p2 

    The article reports that Delcath Systems of New York has entered into an initial launch and training agreement with the European Institute of Oncology (Instituto Europeo de Oncologia, or IEO), a European cancer treatment and research center in Milan, Italy, for the Delcath Hepatic Chemostat...

  • Oncology Nursing Minimum Data Set (ONMDS): can we hypothesize a set of prevalent Nursing Sensitive Outcomes (NSO) in cancer patients? Milani, A.; Mauri, S.; Gandini, S.; Magon, G. // Ecancermedicalscience;2013, Vol. 7 Issue 334-360, p1 

    Background: The nursing minimum data set (NMDS) was created in 1977 in the United States to collect uniform standardised data that could be comparable among different nursing areas or patients. So far, in the literature, an NMDS in an oncology setting has not yet been described. Considering an...

  • Treatment - Radiotherapy.  // Current Medical Literature: Breast Cancer;2010, Vol. 22 Issue 4, p147 

    The article discusses two studies on intraoperative radiotherapy. The first study, conducted by Vaidya et al., presents the results from a collaborative international, randomized, clinical trial, which compared targeted intraoperative radiotherapy against whole breast radiotherapy for breast...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics